Yes, Humira (adalimumab) is an anti-TNF agent.
Humira is a fully humanized monoclonal antibody that specifically targets and inhibits tumor necrosis factor-alpha (TNF-α), making it a TNF inhibitor (anti-TNF agent). 1
Mechanism of Action
Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors 2. This mechanism distinguishes it from other anti-TNF agents in important structural ways:
- Adalimumab is a fully humanized anti-TNF-α monoclonal antibody that cannot be distinguished from normal human IgG1 1
- It differs from infliximab (a chimeric mouse/human antibody with ~25% mouse-derived protein) 3
- It differs from etanercept (a fusion protein consisting of TNF receptor portions rather than an antibody) 3, 1
Clinical Classification
The FDA-approved drug label explicitly states that HUMIRA is a tumor necrosis factor (TNF) blocker 2. Multiple authoritative guidelines consistently classify adalimumab within the anti-TNF class of biological agents 1, 4, 1, 5, 6.
The anti-TNF class includes five approved agents: infliximab, adalimumab, certolizumab pegol, etanercept, and golimumab 1. Among these, adalimumab and golimumab are the only fully humanized monoclonal antibodies 1.
Approved Indications
As an anti-TNF agent, adalimumab is approved for multiple inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, juvenile idiopathic arthritis, hidradenitis suppurativa, and uveitis 4, 5, 2.